Figure 1.

 Summary of patient disposition, including the number of patients who were randomised to each treatment, entered early escape, discontinued treatment, and/or completed the study, in a controlled trial of infliximab and placebo in patients with PsA. *Three patients in the placebo group received infliximab at the first infusion in error and were not included in the safety analysis in the placebo group; †patients who discontinued treatment remained in the study and returned for evaluations; ‡all patients who discontinued the study are counted in the total patients who discontinued treatment.